Mary Degroote is an Infectious Disease physician affiliated with University of Colorado Anschutz Medical Campus. OpenAlex indexes 21 publications with 1,250 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3885 Upham St
Ste 200
Wheat Ridge, CO 800334880
Telephone
303-425-9245Registry record last updated 17 Jun 2011.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Paratek Pharmaceuticals, Inc.Program year20221 payment
- ABBVIE INC.Program year20221 payment
- AbbVie Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Cephalosporin Antibacterial100%Cefazolin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2014–2016 per NIH RePORTER. The latest:
- Optimization and Lead Selection of Novel Antimycobacterial Agents
Crestone, Inc.
FY2016$716,061R44GM110848 - Optimization and Lead Selection of Novel Antimycobacterial Agents
Crestone, Inc.
FY2015$761,426R44GM110848 - Optimization and Lead Selection of Novel Antimycobacterial Agents
Crestone, Inc.
FY2014$150,000R43GM110848
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of a Mock Week as a Novel Tool for Evaluating and Implementing Reformed Medical Curriculum at a Nascent Branch Campus
Journal of Regional Medical Campuses
2021 - Discovery of benzothiazole amides as potent antimycobacterial agents
Bioorganic & Medicinal Chemistry Letters
2018 - Mycobacterium talmoniae sp. nov., a slowly growing mycobacterium isolated from human respiratory samples
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
2017 - Treatment of Non-Tuberculous Mycobacterial Lung Disease
Current treatment options in infectious diseases/Current treatment options in infectious disease
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Schulick, MD, MBA
University of Colorado Anschutz Medical Campus
John Rumsfeld, MD, PhD
University of Colorado Anschutz Medical Campus
Robert Eckel, MD
University of Colorado Anschutz Medical Campus
Marc Bonaca, MD
University of Colorado Anschutz Medical Campus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”